Selected research
Industry Research
Trigger Point Injections Drugs Industry Research Report 2026
Market perspective
The global Trigger Point Injections Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Trigger Point Injections Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Trigger Point Injections Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Trigger Point Injections Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Trigger Point Injections Drugs include Allergan, Anuh Pharma, Axplora, Boehringer Ingelheim, Bristol Myers Squibb, Cipla, EUROAPI, GlaxoSmithKline and Hospira, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Trigger Point Injections Drugs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Trigger Point Injections Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Trigger Point Injections Drugs Market by Company
Allergan
Anuh Pharma
Axplora
Boehringer Ingelheim
Bristol Myers Squibb
Cipla
EUROAPI
GlaxoSmithKline
Hospira
Hovione
Ipsen
Regeneron Pharmaceuticals
Steroid
Symbiotec Pharmalab
Teva Pharmaceuticals
Wellona Pharma
Zimmer Biomet
Bayer
GSK
Pfizer
Mylan
Sun Pharmaceutical
Trigger Point Injections Drugs Segment by Type
Botulinum Toxin (Botox)
Corticosteroids
Local Anesthetics
Platelet-Rich Plasma (PRP)
Other Agents
Trigger Point Injections Drugs Segment by Application
Surgical
Medical Diagnosis
Intensive Care Area (ICU)
Trigger Point Injections Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Trigger Point Injections Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Trigger Point Injections Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Trigger Point Injections Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Trigger Point Injections Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Botulinum Toxin (Botox)
- Corticosteroids
- Local Anesthetics
- Platelet-Rich Plasma (PRP)
- Other Agents
Applications
- Surgical
- Medical Diagnosis
- Intensive Care Area (ICU)
Companies covered
- Allergan
- Anuh Pharma
- Axplora
- Boehringer Ingelheim
- Bristol Myers Squibb
- Cipla
- EUROAPI
- GlaxoSmithKline
- Hospira
- Hovione
- Ipsen
- Regeneron Pharmaceuticals
- Steroid
- Symbiotec Pharmalab
- Teva Pharmaceuticals
- Wellona Pharma
- Zimmer Biomet
- Bayer
- GSK
- Pfizer
- Mylan
- Sun Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Trigger Point Injections Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Botulinum Toxin (Botox)
- 2.2.3 Corticosteroids
- 2.2.4 Local Anesthetics
- 2.2.5 Platelet-Rich Plasma (PRP)
- 2.2.6 Other Agents
- 2.3 Trigger Point Injections Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Surgical
- 2.3.3 Medical Diagnosis
- 2.3.4 Intensive Care Area (ICU)
- 2.4 Assumptions and Limitations
3 Trigger Point Injections Drugs Breakdown Data by Type
- 3.1 Global Trigger Point Injections Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Trigger Point Injections Drugs Forecasted Market Size by Type (2027-2032)
4 Trigger Point Injections Drugs Breakdown Data by Application
- 4.1 Global Trigger Point Injections Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Trigger Point Injections Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Trigger Point Injections Drugs Market Perspective (2021-2032)
- 5.2 Global Trigger Point Injections Drugs Growth Trends by Region
- 5.2.1 Global Trigger Point Injections Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Trigger Point Injections Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Trigger Point Injections Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Trigger Point Injections Drugs Market Dynamics
- 5.3.1 Trigger Point Injections Drugs Industry Trends
- 5.3.2 Trigger Point Injections Drugs Market Drivers
- 5.3.3 Trigger Point Injections Drugs Market Challenges
- 5.3.4 Trigger Point Injections Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Trigger Point Injections Drugs Players by Revenue
- 6.1.1 Global Top Trigger Point Injections Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Trigger Point Injections Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Trigger Point Injections Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Trigger Point Injections Drugs Head Office and Area Served
- 6.4 Global Trigger Point Injections Drugs Players, Product Type & Application
- 6.5 Global Trigger Point Injections Drugs Manufacturers Established Date
- 6.6 Global Trigger Point Injections Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Trigger Point Injections Drugs Market Size (2021-2032)
- 7.2 North America Trigger Point Injections Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Trigger Point Injections Drugs Market Size by Country (2021-2026)
- 7.4 North America Trigger Point Injections Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Trigger Point Injections Drugs Market Size (2021-2032)
- 8.2 Europe Trigger Point Injections Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Trigger Point Injections Drugs Market Size by Country (2021-2026)
- 8.4 Europe Trigger Point Injections Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Trigger Point Injections Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Trigger Point Injections Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Trigger Point Injections Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Trigger Point Injections Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Trigger Point Injections Drugs Market Size (2021-2032)
- 10.2 South America Trigger Point Injections Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Trigger Point Injections Drugs Market Size by Country (2021-2026)
- 10.4 South America Trigger Point Injections Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Trigger Point Injections Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Trigger Point Injections Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Trigger Point Injections Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Trigger Point Injections Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Allergan
- 12.1.1 Allergan Company Information
- 12.1.2 Allergan Business Overview
- 12.1.3 Allergan Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.1.4 Allergan Trigger Point Injections Drugs Product Portfolio
- 12.1.5 Allergan Recent Developments
- 12.2 Anuh Pharma
- 12.2.1 Anuh Pharma Company Information
- 12.2.2 Anuh Pharma Business Overview
- 12.2.3 Anuh Pharma Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.2.4 Anuh Pharma Trigger Point Injections Drugs Product Portfolio
- 12.2.5 Anuh Pharma Recent Developments
- 12.3 Axplora
- 12.3.1 Axplora Company Information
- 12.3.2 Axplora Business Overview
- 12.3.3 Axplora Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.3.4 Axplora Trigger Point Injections Drugs Product Portfolio
- 12.3.5 Axplora Recent Developments
- 12.4 Boehringer Ingelheim
- 12.4.1 Boehringer Ingelheim Company Information
- 12.4.2 Boehringer Ingelheim Business Overview
- 12.4.3 Boehringer Ingelheim Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.4.4 Boehringer Ingelheim Trigger Point Injections Drugs Product Portfolio
- 12.4.5 Boehringer Ingelheim Recent Developments
- 12.5 Bristol Myers Squibb
- 12.5.1 Bristol Myers Squibb Company Information
- 12.5.2 Bristol Myers Squibb Business Overview
- 12.5.3 Bristol Myers Squibb Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.5.4 Bristol Myers Squibb Trigger Point Injections Drugs Product Portfolio
- 12.5.5 Bristol Myers Squibb Recent Developments
- 12.6 Cipla
- 12.6.1 Cipla Company Information
- 12.6.2 Cipla Business Overview
- 12.6.3 Cipla Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.6.4 Cipla Trigger Point Injections Drugs Product Portfolio
- 12.6.5 Cipla Recent Developments
- 12.7 EUROAPI
- 12.7.1 EUROAPI Company Information
- 12.7.2 EUROAPI Business Overview
- 12.7.3 EUROAPI Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.7.4 EUROAPI Trigger Point Injections Drugs Product Portfolio
- 12.7.5 EUROAPI Recent Developments
- 12.8 GlaxoSmithKline
- 12.8.1 GlaxoSmithKline Company Information
- 12.8.2 GlaxoSmithKline Business Overview
- 12.8.3 GlaxoSmithKline Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.8.4 GlaxoSmithKline Trigger Point Injections Drugs Product Portfolio
- 12.8.5 GlaxoSmithKline Recent Developments
- 12.9 Hospira
- 12.9.1 Hospira Company Information
- 12.9.2 Hospira Business Overview
- 12.9.3 Hospira Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.9.4 Hospira Trigger Point Injections Drugs Product Portfolio
- 12.9.5 Hospira Recent Developments
- 12.10 Hovione
- 12.10.1 Hovione Company Information
- 12.10.2 Hovione Business Overview
- 12.10.3 Hovione Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.10.4 Hovione Trigger Point Injections Drugs Product Portfolio
- 12.10.5 Hovione Recent Developments
- 12.11 Ipsen
- 12.11.1 Ipsen Company Information
- 12.11.2 Ipsen Business Overview
- 12.11.3 Ipsen Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.11.4 Ipsen Trigger Point Injections Drugs Product Portfolio
- 12.11.5 Ipsen Recent Developments
- 12.12 Regeneron Pharmaceuticals
- 12.12.1 Regeneron Pharmaceuticals Company Information
- 12.12.2 Regeneron Pharmaceuticals Business Overview
- 12.12.3 Regeneron Pharmaceuticals Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.12.4 Regeneron Pharmaceuticals Trigger Point Injections Drugs Product Portfolio
- 12.12.5 Regeneron Pharmaceuticals Recent Developments
- 12.13 Steroid
- 12.13.1 Steroid Company Information
- 12.13.2 Steroid Business Overview
- 12.13.3 Steroid Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.13.4 Steroid Trigger Point Injections Drugs Product Portfolio
- 12.13.5 Steroid Recent Developments
- 12.14 Symbiotec Pharmalab
- 12.14.1 Symbiotec Pharmalab Company Information
- 12.14.2 Symbiotec Pharmalab Business Overview
- 12.14.3 Symbiotec Pharmalab Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.14.4 Symbiotec Pharmalab Trigger Point Injections Drugs Product Portfolio
- 12.14.5 Symbiotec Pharmalab Recent Developments
- 12.15 Teva Pharmaceuticals
- 12.15.1 Teva Pharmaceuticals Company Information
- 12.15.2 Teva Pharmaceuticals Business Overview
- 12.15.3 Teva Pharmaceuticals Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.15.4 Teva Pharmaceuticals Trigger Point Injections Drugs Product Portfolio
- 12.15.5 Teva Pharmaceuticals Recent Developments
- 12.16 Wellona Pharma
- 12.16.1 Wellona Pharma Company Information
- 12.16.2 Wellona Pharma Business Overview
- 12.16.3 Wellona Pharma Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.16.4 Wellona Pharma Trigger Point Injections Drugs Product Portfolio
- 12.16.5 Wellona Pharma Recent Developments
- 12.17 Zimmer Biomet
- 12.17.1 Zimmer Biomet Company Information
- 12.17.2 Zimmer Biomet Business Overview
- 12.17.3 Zimmer Biomet Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.17.4 Zimmer Biomet Trigger Point Injections Drugs Product Portfolio
- 12.17.5 Zimmer Biomet Recent Developments
- 12.18 Bayer
- 12.18.1 Bayer Company Information
- 12.18.2 Bayer Business Overview
- 12.18.3 Bayer Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.18.4 Bayer Trigger Point Injections Drugs Product Portfolio
- 12.18.5 Bayer Recent Developments
- 12.19 GSK
- 12.19.1 GSK Company Information
- 12.19.2 GSK Business Overview
- 12.19.3 GSK Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.19.4 GSK Trigger Point Injections Drugs Product Portfolio
- 12.19.5 GSK Recent Developments
- 12.20 Pfizer
- 12.20.1 Pfizer Company Information
- 12.20.2 Pfizer Business Overview
- 12.20.3 Pfizer Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.20.4 Pfizer Trigger Point Injections Drugs Product Portfolio
- 12.20.5 Pfizer Recent Developments
- 12.21 Mylan
- 12.21.1 Mylan Company Information
- 12.21.2 Mylan Business Overview
- 12.21.3 Mylan Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.21.4 Mylan Trigger Point Injections Drugs Product Portfolio
- 12.21.5 Mylan Recent Developments
- 12.22 Sun Pharmaceutical
- 12.22.1 Sun Pharmaceutical Company Information
- 12.22.2 Sun Pharmaceutical Business Overview
- 12.22.3 Sun Pharmaceutical Revenue in Trigger Point Injections Drugs Business (2021-2026)
- 12.22.4 Sun Pharmaceutical Trigger Point Injections Drugs Product Portfolio
- 12.22.5 Sun Pharmaceutical Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst